overactive bladder
Urology · 2007–2023
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| oxybutynin Overactive bladder with symptoms of urinary frequency, urgency or incontinence in patients unable to tolerate or swallow oral oxybutynin. | Nov 2023 | Noted | none received |
| botulinum toxin type A Treatment of urinary incontinence due to idiopathic overactive bladder (iOAB) in patients with ≥14 episodes/week who are willing to self-catheterise and have… | Nov 2013 | Recommended with restriction | unclear |
| oxybutynin Treatment of symptoms of urge urinary incontinence and urgency in patients with overactive bladder. | Mar 2008 | Not recommended | no section in document |
| solifenacin succinate Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency in patients where treatment with oxybutynin… | Jul 2007 | Recommended | no section in document |
| solifenacin succinate Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency in patients where treatment with oxybutynin… | Jul 2007 | Recommended | no section in document |
What the PBS pays
$80M in government benefit over 2024–25, across 555,825 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
| oxybutynin | $7.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| mirabegronMirabegron for treating symptoms of overactive bladder | TA290 | not recommended | 2013-06 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| darifenacinENABLEX darifenacin 15mg (as hydrobromide) modified release tablet bli | 2005 | 6 |
| botulinim toxin type aBOTOX botulinum toxin type A purified neurotoxin complex 200U injectio | 1999 | 3 |
| mirabegronBETMIGA mirabegron 25 mg film-coated prolonged-release tablet blister | 2013 | 2 |
| tolterodineDETRUSITOL tolterodine tartrate 1mg tablet blister pack | 2004 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.